Impact of single dose of diethylcarbamazine and other antifilarial drug combinations on bancroftian filarial infection variables: assessment after 2 years.
Identifieur interne : 003952 ( PubMed/Corpus ); précédent : 003951; suivant : 003953Impact of single dose of diethylcarbamazine and other antifilarial drug combinations on bancroftian filarial infection variables: assessment after 2 years.
Auteurs : I P Sunish ; R. Rajendran ; T R Mani ; A. Munirathinam ; R. Reuben ; A P DashSource :
- Parasitology international [ 1383-5769 ] ; 2006.
English descriptors
- KwdEn :
- Albendazole (administration & dosage), Albendazole (therapeutic use), Animals, Diethylcarbamazine (administration & dosage), Diethylcarbamazine (therapeutic use), Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Female, Filaricides (administration & dosage), Filaricides (therapeutic use), Humans, India, Ivermectin (administration & dosage), Ivermectin (therapeutic use), Male, Rural Population, Wuchereria bancrofti.
- MESH :
- chemical , administration & dosage : Albendazole, Diethylcarbamazine, Filaricides, Ivermectin.
- chemical , therapeutic use : Albendazole, Diethylcarbamazine, Filaricides, Ivermectin.
- geographic : India.
- drug therapy : Elephantiasis, Filarial.
- Animals, Drug Therapy, Combination, Female, Humans, Male, Rural Population, Wuchereria bancrofti.
Abstract
The impact of single dose mass drug administration of diethylcarbamazine (DEC), DEC with albendazole (ALB), and ivermectin (IVR) with albendazole, was examined on the human bancroftian filarial infections in village scale trials in south India, from a follow-up study after 2 years. The treatment arms administered with DEC alone and DEC+ALB demonstrated long-term benefits in reducing microfilaraemia significantly (P<0.05), while antigenaemia reduction was negligible. The arm with ALB+IVR did not show such reductions. Among the antigenaemic and microfilaraemic individuals, 87% became amicrofilaraemic in DEC+ALB arm, which were higher than that observed in the other 2 treatment arms. Among amicrofilaraemics (but Ag+), nearly 35% cleared of infection in DEC+ALB, while 26% and 6% in DEC alone and IVR+ALB arms, respectively. The drug combination DEC+ALB was observed to demonstrate a significant impact in reducing filarial infection even after 2 years post treatment.
DOI: 10.1016/j.parint.2006.05.003
PubMed: 16807079
Links to Exploration step
pubmed:16807079Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of single dose of diethylcarbamazine and other antifilarial drug combinations on bancroftian filarial infection variables: assessment after 2 years.</title>
<author><name sortKey="Sunish, I P" sort="Sunish, I P" uniqKey="Sunish I" first="I P" last="Sunish">I P Sunish</name>
<affiliation><nlm:affiliation>Centre for Research in Medical Entomology (Indian Council of Medical Research), 4 Sarojini Street, Chinna Chokkikulam, Madurai-625 002, Tamil Nadu, India. crmeicmr@icmr.org.in</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rajendran, R" sort="Rajendran, R" uniqKey="Rajendran R" first="R" last="Rajendran">R. Rajendran</name>
</author>
<author><name sortKey="Mani, T R" sort="Mani, T R" uniqKey="Mani T" first="T R" last="Mani">T R Mani</name>
</author>
<author><name sortKey="Munirathinam, A" sort="Munirathinam, A" uniqKey="Munirathinam A" first="A" last="Munirathinam">A. Munirathinam</name>
</author>
<author><name sortKey="Reuben, R" sort="Reuben, R" uniqKey="Reuben R" first="R" last="Reuben">R. Reuben</name>
</author>
<author><name sortKey="Dash, A P" sort="Dash, A P" uniqKey="Dash A" first="A P" last="Dash">A P Dash</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16807079</idno>
<idno type="pmid">16807079</idno>
<idno type="doi">10.1016/j.parint.2006.05.003</idno>
<idno type="wicri:Area/PubMed/Corpus">003952</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003952</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of single dose of diethylcarbamazine and other antifilarial drug combinations on bancroftian filarial infection variables: assessment after 2 years.</title>
<author><name sortKey="Sunish, I P" sort="Sunish, I P" uniqKey="Sunish I" first="I P" last="Sunish">I P Sunish</name>
<affiliation><nlm:affiliation>Centre for Research in Medical Entomology (Indian Council of Medical Research), 4 Sarojini Street, Chinna Chokkikulam, Madurai-625 002, Tamil Nadu, India. crmeicmr@icmr.org.in</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rajendran, R" sort="Rajendran, R" uniqKey="Rajendran R" first="R" last="Rajendran">R. Rajendran</name>
</author>
<author><name sortKey="Mani, T R" sort="Mani, T R" uniqKey="Mani T" first="T R" last="Mani">T R Mani</name>
</author>
<author><name sortKey="Munirathinam, A" sort="Munirathinam, A" uniqKey="Munirathinam A" first="A" last="Munirathinam">A. Munirathinam</name>
</author>
<author><name sortKey="Reuben, R" sort="Reuben, R" uniqKey="Reuben R" first="R" last="Reuben">R. Reuben</name>
</author>
<author><name sortKey="Dash, A P" sort="Dash, A P" uniqKey="Dash A" first="A P" last="Dash">A P Dash</name>
</author>
</analytic>
<series><title level="j">Parasitology international</title>
<idno type="ISSN">1383-5769</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (administration & dosage)</term>
<term>Albendazole (therapeutic use)</term>
<term>Animals</term>
<term>Diethylcarbamazine (administration & dosage)</term>
<term>Diethylcarbamazine (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Female</term>
<term>Filaricides (administration & dosage)</term>
<term>Filaricides (therapeutic use)</term>
<term>Humans</term>
<term>India</term>
<term>Ivermectin (administration & dosage)</term>
<term>Ivermectin (therapeutic use)</term>
<term>Male</term>
<term>Rural Population</term>
<term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term>
<term>Diethylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term>
<term>Diethylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>India</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Rural Population</term>
<term>Wuchereria bancrofti</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The impact of single dose mass drug administration of diethylcarbamazine (DEC), DEC with albendazole (ALB), and ivermectin (IVR) with albendazole, was examined on the human bancroftian filarial infections in village scale trials in south India, from a follow-up study after 2 years. The treatment arms administered with DEC alone and DEC+ALB demonstrated long-term benefits in reducing microfilaraemia significantly (P<0.05), while antigenaemia reduction was negligible. The arm with ALB+IVR did not show such reductions. Among the antigenaemic and microfilaraemic individuals, 87% became amicrofilaraemic in DEC+ALB arm, which were higher than that observed in the other 2 treatment arms. Among amicrofilaraemics (but Ag+), nearly 35% cleared of infection in DEC+ALB, while 26% and 6% in DEC alone and IVR+ALB arms, respectively. The drug combination DEC+ALB was observed to demonstrate a significant impact in reducing filarial infection even after 2 years post treatment.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16807079</PMID>
<DateCreated><Year>2006</Year>
<Month>07</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted><Year>2006</Year>
<Month>09</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1383-5769</ISSN>
<JournalIssue CitedMedium="Print"><Volume>55</Volume>
<Issue>3</Issue>
<PubDate><Year>2006</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Parasitology international</Title>
<ISOAbbreviation>Parasitol. Int.</ISOAbbreviation>
</Journal>
<ArticleTitle>Impact of single dose of diethylcarbamazine and other antifilarial drug combinations on bancroftian filarial infection variables: assessment after 2 years.</ArticleTitle>
<Pagination><MedlinePgn>233-6</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The impact of single dose mass drug administration of diethylcarbamazine (DEC), DEC with albendazole (ALB), and ivermectin (IVR) with albendazole, was examined on the human bancroftian filarial infections in village scale trials in south India, from a follow-up study after 2 years. The treatment arms administered with DEC alone and DEC+ALB demonstrated long-term benefits in reducing microfilaraemia significantly (P<0.05), while antigenaemia reduction was negligible. The arm with ALB+IVR did not show such reductions. Among the antigenaemic and microfilaraemic individuals, 87% became amicrofilaraemic in DEC+ALB arm, which were higher than that observed in the other 2 treatment arms. Among amicrofilaraemics (but Ag+), nearly 35% cleared of infection in DEC+ALB, while 26% and 6% in DEC alone and IVR+ALB arms, respectively. The drug combination DEC+ALB was observed to demonstrate a significant impact in reducing filarial infection even after 2 years post treatment.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sunish</LastName>
<ForeName>I P</ForeName>
<Initials>IP</Initials>
<AffiliationInfo><Affiliation>Centre for Research in Medical Entomology (Indian Council of Medical Research), 4 Sarojini Street, Chinna Chokkikulam, Madurai-625 002, Tamil Nadu, India. crmeicmr@icmr.org.in</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rajendran</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mani</LastName>
<ForeName>T R</ForeName>
<Initials>TR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Munirathinam</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Reuben</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Dash</LastName>
<ForeName>A P</ForeName>
<Initials>AP</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2006</Year>
<Month>06</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Parasitol Int</MedlineTA>
<NlmUniqueID>9708549</NlmUniqueID>
<ISSNLinking>1383-5769</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005369">Filaricides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>70288-86-7</RegistryNumber>
<NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>F4216019LN</RegistryNumber>
<NameOfSubstance UI="D015766">Albendazole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber>
<NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012424" MajorTopicYN="N">Rural Population</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014958" MajorTopicYN="Y">Wuchereria bancrofti</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year>
<Month>01</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2006</Year>
<Month>05</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2006</Year>
<Month>05</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>6</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>9</Month>
<Day>27</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>6</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16807079</ArticleId>
<ArticleId IdType="pii">S1383-5769(06)00077-8</ArticleId>
<ArticleId IdType="doi">10.1016/j.parint.2006.05.003</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003952 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003952 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:16807079 |texte= Impact of single dose of diethylcarbamazine and other antifilarial drug combinations on bancroftian filarial infection variables: assessment after 2 years. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16807079" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |